Trump-Inspired World Liberty Financial Closes $550 Million Across Token Sales
17.3.2025 20:37:00 CET | Business Wire | Press release
WLFI completes second set of WLFI governance token sales
World Liberty Financial, Inc. (“WLFI”), the developer of a pioneering DeFi protocol and governance platform inspired by Donald J. Trump, has made history with the completion of the second set of its token sales, totaling $550 million in gross proceeds in concurrent U.S. and non-U.S. token offerings.
After launching on October 15, 2024, WLFI has successfully concluded two sets of token sales in concurrent U.S. and non-U.S. offerings. In the first set, $300 million USD of WLFI tokens were sold between the offerings, and in the second set, $250 million USD of WLFI tokens were sold between the offerings. Between all the offerings, $550 million USD in WLFI tokens have been sold.
More than 85,000 total participants in the token sales underwent Know Your Customer (KYC) process to determine participation eligibility.
"This milestone proves that those who truly understand crypto and finance recognize what we’re building — and that WLFI is on track to supercharge DeFi as it transforms global finance in the coming years," said Zach Witkoff, WLFI co-founder. "World Liberty Financial is grateful to WLFI’s early supporters and partners who saw the game-changing potential of this project and we look forward to their continued participation in the governance of the WLFI protocol. The token sales are just the beginning. We’re gearing up to launch a wave of disruptive technology that will redefine the boundaries of what’s possible with digital assets."
Over the last six months, WLFI has established key relationships with leading blockchain protocols and institutions including Ondo Finance, Ethena, Chainlink, Sui and Aave. These relationships have positioned WLFI to more rapidly build and deploy its upcoming platform which is being purpose-built to democratize finance for millions.
WLFI’s “Macro Strategy” has also assembled a variety of digital assets in its strategic reserve program including BTC, ETH, TRX, LINK, SUI, and ONDO tokens. The WLFI strategic reserve helps strengthen leading cryptocurrency projects while providing stability to its treasury through diversification before ultimate disposition. The Macro Strategy may be used in part to enable WLFI to fund innovative projects, support ecosystem growth, and create new opportunities within the rapidly evolving DeFi landscape.
WLFI remains committed to advancing its mission to create a more inclusive financial future, backed by strategic partnerships, innovative technologies and a dedicated community. As World Liberty Financial continues to build the future of decentralized finance, stay updated on the latest developments and announcements by following us on X at https://x.com/worldlibertyfi.
About World Liberty Financial
World Liberty Financial (WLFI) is a pioneering decentralized finance (DeFi) protocol and governance platform dedicated to empowering individuals through transparent, accessible, and secure financial solutions. Inspired by the vision of President Donald J. Trump, WLFI seeks to democratize access to DeFi by creating user-friendly tools that bring the benefits of decentralized finance to a broader audience. WLFI plans to be at the forefront of DeFi, offering an intuitive, robust platform that empowers users to participate actively in the financial future.
This communication includes forward looking information about future plans, predictions and expectations that are subject to risks and uncertainties and that may be subject to change.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250317855322/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom